Vimarsana
Biggest News Aggregation in the World

Powered Drug News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Powered Drug. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Powered Drug Today - Breaking & Trending Today

Sanofi, Formation Bio, OpenAI Partner on AI-Powered Drug Discovery - Vimarsana News

Sanofi, Formation Bio, OpenAI Partner on AI-Powered Drug Discovery

Sanofi, Formation Bio, , and OpenAI join forces to leverage AI to accelerate drug development and bring new medicines to patients faster.

AI In Health Care: Powering Patient Outcomes - Healthcare - Vimarsana News

AI In Health Care: Powering Patient Outcomes - Healthcare

With the Health Care & Life Sciences sector under pressure to improve patient outcomes while controlling costs, artificial intelligence and machine learning are quickly becoming indispensable tools.

Source: mondaq.com
Canadian Financing: PharmAla Biotech Offers Non-Brokered Private Placement Up To $3.76M - Pharmala Biotech Hldgs (OTC:PMBHF) - Vimarsana News

Canadian Financing: PharmAla Biotech Offers Non-Brokered Private Placement Up To $3.76M - Pharmala Biotech Hldgs (OTC:PMBHF)

MDXX-class molecules biotech company PharmAla Biotech Holdings Inc. (OTCMKTS: PMBHF) has announced a non-brokered private placement of a minimum of 3.3 million units and a maximum of 16.6 million of its units at a price of $0.22 (CA$0.30) each, corresponding to aggregate gross proceeds of minimum $752,300 (CA$1 million,) and maximum $3.76 (CA$5 million.) 

Follow the Money: AI-Powered Drug Discovery, Remote Access Labs - Vimarsana News

Follow the Money: AI-Powered Drug Discovery, Remote Access Labs

July 1, 2021 July 1, 2021 | Insilico Medicine closes a Series C for AI-powered drug discovery, while other investments fuel remote access labs, natural products, high throughput screening, and more. $550M: VC Fund for Therapeutics for Unmet Needs venBio has announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an oversubscribed fundraise. The capital was raised from existing and new investors, including a broad rang...